NUZ 2.50% 19.5¢ neurizon therapeutics limited

Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity, page-7

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,862 Posts.
    lightbulb Created with Sketch. 2278
    Ok, so everyone should be giving that announcement a big thumbs up.
    This allows us to on to human tests and clearly the solubility issue continues for this style of testing BUT not for MPL and not MPLs.
    It also confirms next tests will be conducted at Leiden on human cells - continuity is a big plus. Very pleased we are not looking to change horses.
    I do think the results are exciting and noted the amount of testing that had to be done to produce the results.
    As we have heard in the past, ASX are VERY skeptical of product positive "claims" made around COVID in announcement and seems this one was no different. I also thank them as the additional information is far more interesting than page one ...
    Onward to human cell testing where I am much more confident of a faster and better result.

    Well done Leiden. I trust your detailed work and diligence to science.

    Well done PharmAust and MPL/MPLs... We have a deadline for tablet delivery so lets get a wiggle on so we have no delay beyond what we already have as our longest pole in the tent.

    adreamer confident of the next phase in the journey
    Last edited by adreamer: 07/04/21
 
watchlist Created with Sketch. Add NUZ (ASX) to my watchlist
(20min delay)
Last
19.5¢
Change
-0.005(2.50%)
Mkt cap ! $94.89M
Open High Low Value Volume
20.0¢ 20.3¢ 19.5¢ $124.5K 628.4K

Buyers (Bids)

No. Vol. Price($)
2 2791 19.5¢
 

Sellers (Offers)

Price($) Vol. No.
20.0¢ 62424 2
View Market Depth
Last trade - 15.39pm 01/11/2024 (20 minute delay) ?
NUZ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.